Press

  Omicia, leading provider of clinical interpretation software and services for genetic testing labs, announced that Matt Tindall has been appointed CEO and a member of the company’s Board of Directors.  

The United Kingdom aims to sequence 100,000 human genomes by 2017. But screening them for disease-causing variants will require innovative software. For the 100,000 Genomes Project, it will use Omicia’s Opal Clinical genome interpretation software to assess which variants are likely to be causing disease.  

Rare Genomics Institute (RG) is an international non-profit that that makes cutting edge research technologies of genome sequencing, physicians and scientists around the world accessible to rare disease patients. In partnership with RG, Omicia is delighted to announce the recipients of this year’s BeHEARD Rare Disease Science Challenge, who will receive free access to Omicia’s …

Genomics England announce that it will be using technology co-developed in a partnership between Omicia and the University of Utah, and exclusively commercialized through Omicia, to interpret the DNA of Britons as part of the 100,000 Genomes Project, a national effort to hasten creation of diagnostics and treatments that are tailored to a person’s genetic …

Omicia, the leading clinical genomics company, today announced that it has been selected by Genomics England to provide clinical interpretation services for the 100,000 Genomes Project. For the first phase of the project Illumina will provide sequencing services, while Omicia will provide interpretation and clinical reports.

Genomics England has selected Omicia to interpret genomic data for the first phase of the UK’s 100,000 Genomes Project.

Omicia is recognized as one of the most innovative startup companies poised to change healthcare.

Omicia today announced it is integrating Phevor™ (Phenotype Driven Variant Ontological Re-ranking tool) into its Opal product offering. Phevor, an algorithm co-developed by the University of Utah and Omicia, accelerates identification of disease-relevant variants in genomic sequences.

Omicia has been selected as a finalist for the Innovation Showcase at VentureBeat’s HealthBeat 2014 event.  As one of 10 finalists selected from dozens of startups in the digital health space, Omicia will have the opportunity to demonstrate how Opal Clinical will improve patient outcomes by increasing the accuracy, speed, and diagnostic yield of NGS …

Disorder-causing mutations are hard to detect — they have to be identified among a host of other, innocuous genetic changes. Omicia’s software tools are profiled as Nature takes a look the tools physicians and researchers use to sift through sequenced genomes in search of such mutations.

Omicia, Inc. today announced that four new world-renowned clinical and genomic scientists will advise the strategic development of Omicia’s clinical diagnostic genome interpretation software, and support the company’s vision of improved patient care through personalized medicine.

Omicia, Inc. today announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by LabCorp for its clinical trials sequencing services.

Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool, pVAAST, to identify genetic mutations that contribute to a person���s increased risk for developing common, complex diseases, such as cancer. The research is published in the May 2014 edition of the journal Nature Biotechnology.

A powerful tool called pVAAST that combines linkage analysis with case control association has been developed to help researchers and clinicians identify disease-causing mutations in families faster and more precisely than ever before.

Omicia’s Martin Reese explains how Phevor–developed in collaboration with the University of Utah and MD Anderson Cancer Center — offers a more automated means of selecting the gene variants that likely play the most pertinent roles in a particular patient’s disease phenotype.

Omicia announced the appointment of Paul Billings, M.D., Ph.D., as Chief Medical Officer. Dr. Billings joins Omicia as genomics expands from the research lab to become a valuable clinical diagnostic tool.

Omicia and colleagues at the USTAR Center for Genetic Discovery and MD Anderson Cancer Center report that they have successfully identified diseases with unknown gene mutations in three separate cases using the collaboratively-developed Phevor (Phenotype Driven Variant Ontological Re-ranking tool).

Phevor works by using algorithms that combine the probabilities of gene mutations being involved in a disease with databases of phenotypes, or the physical manifestation of a disease, and information on gene functions. By combining those factors, Phevor identifies an undiagnosed disease or the most likely candidate gene mutation for causing a disease.

A genetics research center at University of Utah in Salt Lake City and Omicia Inc., a genomic analytics company in Oakland, California are developing systems to make genomic analysis a routine medical diagnostic procedure.

The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc., to make analyzing a patient’s genome as routine as performing a blood test.